The history of Theiler's disease and the search for its aetiology.
Authors: Divers Thomas J, Tomlinson Joy E, Tennant Bud C
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary: Theiler's Disease and Its Aetiological Mystery Theiler's disease, or serum hepatitis, has plagued the equine industry for over a century, characterised by acute hepatic failure in adult horses with high mortality despite low morbidity, typically emerging 4–10 weeks after administration of equine-origin biologics, though cases without prior blood product exposure have been documented. Divers, Tomlinson and Tennant's comprehensive review synthesises a century of clinical observations and pathological findings—predominantly centrilobular hepatocyte necrosis with mononuclear infiltration—alongside early epidemic reports from the 1900s that mirror serum hepatitis outbreaks in humans following yellow fever vaccination, all pointing toward a viral aetiology analogous to human hepatitis B. Recent metagenomics-based investigations have identified equine parvovirus-hepatitis (EqPV-H) as the likely causative agent, representing a significant breakthrough in understanding this historically elusive disease. The rapid disease course, where affected horses either recover completely or succumb within days, combined with the occurrence of subclinical cases, underscores the importance of recognising both clinical and inapparent infections in vaccine safety protocols. For practitioners involved in sourcing and administering biologics, understanding the temporal relationship between product administration and disease onset, alongside the emerging evidence implicating EqPV-H, should inform risk assessment strategies and inform conversations with stud owners and competition yards regarding biosecurity and vaccine procurement decisions.
Read the full abstract on PubMed
Practical Takeaways
- •Be alert to the risk of Theiler's disease in adult horses within 4-10 weeks following administration of equine-origin biologics (blood products, vaccines, immunoglobulins); monitor for acute hepatitis signs
- •Recognize that while morbidity is low, mortality is high in affected cases—early detection and intensive supportive care are critical as horses either die or recover completely within days
- •Understanding EqPV-H as the suspected causative agent may inform future preventive strategies and help distinguish this disease from other causes of acute hepatitis in equine practice
Key Findings
- •Theiler's disease is associated with prior administration of equine-origin biologics 4-10 weeks before clinical onset, though cases without prior blood product administration have been documented
- •The disease presents with low morbidity but high mortality in adult horses only, with clinical course lasting days resulting in either death or complete recovery
- •Recent metagenomics-based studies support equine parvovirus-hepatitis (EqPV-H) as the likely aetiological agent of this 100-year-old disease
- •Historical epidemiology and pathology of Theiler's disease show similarities to serum hepatitis in humans following yellow fever vaccinations in the 1930s-1940s